Initially, Chen and colleagues reported in a pivotal phase I trial an impressive 1-year OS of 95% and a PFS rate of 85% with sorafenib maintenance in 22 FLT3–ITD-positive AML patients [10]. This evidence concerns the gene FLT3 and acute myeloid leukemia.